SCHEMBL26426622

SCHEMBL26426622

Cc1c(-c2nc3ccncc3[nH]2)cnn1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 4/20 0.52
METAP1 P53582 2/20 0.50
METAP2 P50579 1/20 0.50
AURKA O14965 1/20 0.48
ALDH1A1 P00352 3/20 0.48
PKM P14618 2/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
JMJD6 Q6NYC1 1/20 0.47
ADORA3 P0DMS8 1/20 0.45
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
RPS6KA5 O75582 1/20 0.44
HPSE Q9Y251 1/20 0.42
BRD4 O60885 1/20 0.41
NPY5R Q15761 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26426627 0.76 PDE5A (0.51) PDE5AMETAP1METAP2AURKAALDH1A1
SCHEMBL26426629 0.76 AURKA (0.47) PDE5AMETAP1METAP2AURKAALDH1A1
SCHEMBL1170780 0.76 ALDH1A1 (0.68) PDE5AMETAP1METAP2AURKAALDH1A1
SCHEMBL26086754 0.74 TTK (0.47) ALDH1A1KDM4EBRD4KDM4C
SCHEMBL26088603 0.72 PDE5A (0.63) PDE5AMETAP1METAP2AURKAALDH1A1
SCHEMBL26089925 0.71 TTK (0.49) PDE3BPDE3ABRD4KDM4C
SCHEMBL26426692 0.71 PDE5A (0.52) PDE5AMETAP1METAP2AURKAALDH1A1
SCHEMBL14224796 0.71 AURKA (0.48) PDE5AMETAP1METAP2AURKAALDH1A1
SCHEMBL16331618 0.71 ALDH1A1 (0.71) PDE5AMETAP1METAP2AURKAALDH1A1
SCHEMBL879284 0.69 ALDH1A1 (0.50) PDE5AMETAP1METAP2AURKAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2026-03-17 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
EP-4110777-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) 2023-01-04 EP disclosed
CN-115175909-A Pyrrolopyridine and imidazopyridine antiviral compounds 鲁汶天主教大学 2022-10-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS SARS1, TPI1, TPMT PDE5A 1378/4885METAP1 209/4885METAP2 332/4885
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds SARS1, TPMT, ZC3HAV1 PDE5A 2466/4885METAP1 648/4885METAP2 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.